Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-09-06
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 65
- Registration Number
- NCT01936363
- Locations
- 🇪🇸
Research site, Valencia, Spain
Adherence Trial With MS LifeLines ® Services
- First Posted Date
- 2013-07-23
- Last Posted Date
- 2015-02-02
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 306
- Registration Number
- NCT01905527
- Locations
- 🇺🇸
Call EMD Serono Medical Information for information on recruiting sites, Boston, Massachusetts, United States
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-09-26
- Last Posted Date
- 2018-01-05
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 194
- Registration Number
- NCT01693068
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
🇩🇪Research site, München, Germany
🇺🇸Please contact the US Medical Information in, Rockland, Massachusetts, United States
A Multicenter Trial of Sprifermin (AS902330 [Recombinant Human Fibroblast Growth Factor-18]) or Placebo After Microfracture Surgery for Cartilage Injury of the Knee
- Conditions
- Interventions
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 1
- Registration Number
- NCT01689337
Tecemotide (L-BLP25) in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 28
- Registration Number
- NCT01496131
- Locations
- 🇺🇸
Please Contact US Medical Information, Rockland, Massachusetts, United States
MSC2015103B in Solid Tumors
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 28
- Registration Number
- NCT01453387
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
Atacicept Demonstrating Dose RESponSe
- First Posted Date
- 2011-09-26
- Last Posted Date
- 2013-08-21
- Lead Sponsor
- EMD Serono
- Registration Number
- NCT01440231
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 146
- Registration Number
- NCT01390818
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Cancer Therapy and Research Center, San Antonio, Texas, United States
Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus
- First Posted Date
- 2011-06-22
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 33
- Registration Number
- NCT01378377
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸For Recruiting Locations in the US contact US Medical Information in, Rockland, Massachusetts, United States
Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2013-10-22
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 1
- Registration Number
- NCT01369628
- Locations
- 🇺🇸
EMD Serono Inc., One Technology Place, Rockland, Massachusetts, United States